Procaps Group SA (NASDAQ:PROC) — Market Cap & Net Worth
Market Cap & Net Worth: Procaps Group SA (PROC)
Procaps Group SA (NASDAQ:PROC) has a market capitalization of $113.95 Million ($113.95 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18786 globally and #4357 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Procaps Group SA's stock price $1.10 by its total outstanding shares 112824000 (112.82 Million). Also see PROC asset base for a full breakdown of the balance sheet.
Procaps Group SA Market Cap History: 2019 to 2025
Procaps Group SA's market capitalization history from 2019 to 2025. Data shows change from $1.11 Billion to $124.11 Million (-32.02% CAGR). Also see cash efficiency ratio of Procaps Group SA for how efficiently the company converts equity into cash flow.
Procaps Group SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Procaps Group SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Procaps Group SA stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.11x
Procaps Group SA's market cap is 1.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.80x
Procaps Group SA's market cap is 8.80 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.11 Billion | $324.79 Million | -$17.01 Million | 3.42x | N/A |
| 2020 | $1.17 Billion | $331.47 Million | -$10.45 Million | 3.54x | N/A |
| 2021 | $1.10 Billion | $409.74 Million | -$100.86 Million | 2.68x | N/A |
| 2022 | $592.33 Million | $409.92 Million | $42.54 Million | 1.44x | 13.92x |
| 2023 | $459.19 Million | $414.10 Million | $52.20 Million | 1.11x | 8.80x |
Competitor Companies of PROC by Market Capitalization
Companies near Procaps Group SA in the global market cap rankings as of September 18, 2026. Review PROC tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Procaps Group SA by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Procaps Group SA Historical Marketcap From 2019 to 2025
Between 2019 and today, Procaps Group SA's market cap moved from $1.11 Billion to $ 124.11 Million, with a yearly change of -32.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $124.11 Million | -52.99% |
| 2024 | $264.01 Million | -42.51% |
| 2023 | $459.19 Million | -22.48% |
| 2022 | $592.33 Million | -46.15% |
| 2021 | $1.10 Billion | -6.25% |
| 2020 | $1.17 Billion | +5.58% |
| 2019 | $1.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 10th, 2026 the market cap of Procaps Group SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $113.95 Million USD |
| MoneyControl | $113.95 Million USD |
| MarketWatch | $113.95 Million USD |
| marketcap.company | $113.95 Million USD |
| Reuters | $113.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Procaps Group SA
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use… Read more